F-box and leucine rich repeat protein 17Genealiases: FBXO13 · Fbl17 · Fbx13
Q-omics provides the consensus-scored FBXL17 profile across patient tissues and cancer cell-line models. FBXL17 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXL17 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, FBXL17 RNA expression shows 19,338 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where FBXL17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL17 survival associations across molecular data types. FBXL17 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL17 RNA expression–survival associations across cancer types. High FBXL17 expression shows unfavorable associations in OV, UVM and CESC, but favorable associations in KIRC, HNSC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXL17 RNA expression.
This table summarizes FBXL17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL17 shows lower tumor expression in THCA, LUSC, COAD, BLCA, UCEC and KIRC. The THCA box plot shows higher FBXL17 RNA expression in normal versus tumor tissue (log2 FC = −0.848, t-test p < 0.001).
This table shows molecular features associated with FBXL17 in patient tissues and cancer cell lines. In patient samples, FBXL17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and CNS.
